相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pathways mediating VEGF-independent tumor angiogenesis
Napoleone Ferrara
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice
Joerg J. Jacoby et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Targeting the tumour vasculature: insights from physiological angiogenesis
Alicia S. Chung et al.
NATURE REVIEWS CANCER (2010)
PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
Yongping Crawford et al.
CANCER CELL (2009)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
George N. Naumov et al.
CLINICAL CANCER RESEARCH (2009)
Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
John M. L. Ebos et al.
CLINICAL CANCER RESEARCH (2009)
VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy
Joshua I. Greenberg et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
Ronald B. Natale et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival
David J. Gallagher et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels
Erika Iivanainen et al.
MICROVASCULAR RESEARCH (2009)
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
Christina L. Roland et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer
Rudi Bao et al.
MOLECULAR CANCER THERAPEUTICS (2009)
PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment
Emmanuelle di Tomaso et al.
PLOS ONE (2009)
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
Farbod Shojaei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
Yongping Crawford et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
Chunhua Lu et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2008)
Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors
Toshio Kuwai et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Pathways Mediating Resistance to Vascular Endothelial Growth Factor - Targeted Therapy
Lee M. Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer
Cornelis J. A. Punt et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
John V. Heymach et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells
Dhara N. Amin et al.
MICROVASCULAR RESEARCH (2008)
A role for VEGF as a negative regulator of pericyte function and vessel maturation
Joshua I. Greenberg et al.
NATURE (2008)
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
Christian Stockmann et al.
NATURE (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Role of myeloid cells in tumor angiogenesis and growth
Farbod Shojaei et al.
TRENDS IN CELL BIOLOGY (2008)
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting
Kristian Pietras et al.
PLOS MEDICINE (2008)
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors
Toshio Kuwai et al.
NEOPLASIA (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
Wenjuan Wu et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Farbod Shojaei et al.
NATURE BIOTECHNOLOGY (2007)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer
Gert G. Van den Eynden et al.
CLINICAL & EXPERIMENTAL METASTASIS (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
M Franco et al.
CANCER RESEARCH (2006)
Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors
DN Amin et al.
CANCER RESEARCH (2006)
Construction of a novel constitutively active chimeric EGFR to identify new targets for therapy
H Cheng et al.
NEOPLASIA (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
T Mukohara et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AN1424) to prevent chemotherapy induced peripheral neuropathy
ID Davis et al.
CLINICAL CANCER RESEARCH (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option
WPJ Leenders et al.
CLINICAL CANCER RESEARCH (2004)
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
JV Heymach et al.
CLINICAL CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
RT Tong et al.
CANCER RESEARCH (2004)
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences
HJ Broxterman et al.
DRUG RESISTANCE UPDATES (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
Effect of p53 status on tumor response to antiangiogenic therapy
JL Yu et al.
SCIENCE (2002)
Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival
A Giatromanolaki et al.
BRITISH JOURNAL OF CANCER (2001)
Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice
F Paris et al.
SCIENCE (2001)
Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches
RS Kerbel et al.
CANCER AND METASTASIS REVIEWS (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
分享论文
